187 related articles for article (PubMed ID: 35903892)
1. Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma.
Colomba E; Alves Costa Silva C; Le Teuff G; Elmawieh J; Afonso D; Benchimol-Zouari A; Guida A; Derosa L; Flippot R; Raynard B; Escudier B; Bidault F; Albiges L
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2405-2416. PubMed ID: 35903892
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib.
Buchler T; Kopecka M; Zemankova A; Wiesnerová M; Streckova E; Rozsypalova A; Melichar B; Poprach A; Richter I
Target Oncol; 2020 Oct; 15(5):673-679. PubMed ID: 32748047
[TBL] [Abstract][Full Text] [Related]
3. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
5. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM; Harris WB; Kucuk O; Master VA; Bilen MA
Cancer Treat Res Commun; 2021; 28():100393. PubMed ID: 34029879
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials.
McElwee JH; Gourdin TS; Mikoll J; Weeda E; Sion AM
J Oncol Pharm Pract; 2020 Jun; 26(4):861-865. PubMed ID: 31566113
[TBL] [Abstract][Full Text] [Related]
9. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Loo Gan C; Huang J; Pan E; Xie W; Schmidt AL; Labaki C; Meza L; Bouchard G; Li H; Jackson-Spence F; Sánchez-Ruiz C; Powles T; Kumar SA; Weise N; Hall WA; Rose BS; Beuselinck B; Suarez C; Pal SK; Choueiri TK; Heng DYC; McKay RR
Eur Urol Oncol; 2023 Apr; 6(2):204-211. PubMed ID: 36328934
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
Iacovelli R; Ciccarese C; Fornarini G; Massari F; Bimbatti D; Mosillo C; Rebuzzi SE; Di Nunno V; Grassi M; Fantinel E; Ardizzoni A; Tortora G
Br J Clin Pharmacol; 2019 Jun; 85(6):1283-1289. PubMed ID: 30740760
[TBL] [Abstract][Full Text] [Related]
14. Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
Bodnar L; Kopczyńska A; Żołnierek J; Wieczorek-Rutkowska M; Chrom P; Tomczak P
Clin Genitourin Cancer; 2019 Jun; 17(3):e556-e564. PubMed ID: 30987807
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
Iacovelli R; Ciccarese C; Facchini G; Milella M; Urbano F; Basso U; De Giorgi U; Sabbatini R; Santini D; Berardi R; Santoni M; Bracarda S; Massari F; Masini C; De Tursi M; Ricotta R; Buti S; Zustovich F; Sepe P; Rossetti S; Maruzzo M; Cortesi E; Tortora G; Procopio G
Target Oncol; 2020 Aug; 15(4):495-501. PubMed ID: 32671807
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
Rassy E; Cerbone L; Auclin E; Benchimoll-Zouari A; Flippot R; Alves Costa Silva C; Colomba E; Geraud A; Guida A; Mir O; Combarel D; Paci A; Escudier B; Albiges L
Oncologist; 2021 May; 26(5):389-396. PubMed ID: 33554383
[TBL] [Abstract][Full Text] [Related]
17. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.
Lacy S; Nielsen J; Yang B; Miles D; Nguyen L; Hutmacher M
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1061-1070. PubMed ID: 29667066
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
Damassi A; Cremante M; Signori A; Rebuzzi SE; Fornarini G; Giudice GC; Maruzzo M; Procopio G; Sorarù M; Di Napoli M; Fratino L; Santini D; Grillone F; Ballestrin M; Dionese M; Nasso C; Catalano F; Murianni V; Rescigno P; Anpalakhan S; Banna GL; Basso U; Buti S
Clin Genitourin Cancer; 2024 Apr; 22(2):126-133.e2. PubMed ID: 37932204
[TBL] [Abstract][Full Text] [Related]
19. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M
Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997
[TBL] [Abstract][Full Text] [Related]
20. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
